The Role of Mass Spectrometry in Demonstrating Biosimilarity

Mass spectrometry helps determine and confirm the primary structure of biosimilars as part of analytical comparability activities. Certain mass spectrometry techniques can be used to define and characterize post-translational modifications (PTMs). Characterization includes identity and structural analysis of the modification as well as location and occupancy of PTM(s) within the primary structure of the respective biosimilar molecules.

During this webinar, we provide an overview of various mass spectrometry techniques available and how to apply these methodologies for biosimilar characterization.


  • Mario Dipaola, PhD, MBA, Senior Scientific Director, Charles River

Please see the links below for the other webinars in the series:

Use of CROs to Speed the Development of Biosimilars

MoA Reflecting Bioassays to Confirm Biosimilarity

Nonclinical and Clinical Bioanalytical Assay Requirements for Biosimilar Drug Development